Skip to main content
TipRanks
Go Ultimate75% OFF

MediPharm Labs (MLZ) AI Stock Analysis

1 Followers
DE:MLZ

MediPharm Labs

(Frankfurt:MLZ)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
International medical growthInternational medical channels are becoming a central revenue engine, reducing reliance on any single market and supporting broader commercial diversification. Growth in Germany, the U.K. and other regulated markets can strengthen customer access and create a more durable platform for future product expansion.
Negative Factors
Negative free cash flowNegative free cash flow means the business is not yet consistently self-funding after investment needs, even though operating cash flow has improved. Persistent cash conversion weakness could constrain expansion, require tighter capital allocation and delay the point at which reported operating progress becomes financially self-sustaining.

MediPharm Labs (MLZ) vs. iShares MSCI Germany ETF (EWG)

-20%-10%0%10%20%30%40%50%DE:MLZ-8.33%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 20.08M
Dividend Yield
―
Average Volume (3M)
2,910
Price to Earnings (P/E)
-9.2
Beta (1Y)
-0.24
Revenue Growth
-13.17%
EPS Growth
67.74%
Country
Germany
Employees
127
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

MediPharm Labs Business Overview & Revenue Model

Company Description

MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across C...

MediPharm Labs Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:May 10, 2019
Earnings Call SentimentPositive

The call was predominantly positive. MediPharm reported 18% sequential revenue growth, strong international medical performance, positive net income for the second consecutive quarter, positive adjusted EBITDA for the third consecutive quarter, lower operating expenses and a strong balance sheet. These achievements outweighed the stated challenges in Australia, the impact of Veterans Affairs Canada reimbursement changes, the year-to-date revenue decline versus the prior year and the sequential gross margin decrease.

Positive Updates

Disciplined M&A Strategy
MediPharm continues to evaluate selective M&A opportunities focused on regulated medical markets, capabilities, market access and the quality and sustainability of earnings. Since the VIVO transaction, the company has evaluated multiple opportunities while maintaining discipline on valuation, strategic fit, integration risk and capital use.

Negative Updates

Australian Market Challenges
Australia remained challenging in Q3 as regulatory scrutiny, changing prescribing behavior, price compression and channel inventory reductions weighed on revenue. Management said the market is undergoing normalization and that the recovery will take time.

Company Guidance

Management said Australia’s recovery will take time, but the actions taken are believed to better align the portfolio with evolving patient demand and position the business for improved performance over time. The Q1 restructuring initiatives are expected to generate more than $1 million in annualized savings. MediPharm intends to continue expanding in regulated medical markets, pursue future commercialization of its metered dose inhaler in the U.K. and European Union, and evaluate selective M&A opportunities that meet its return thresholds. Brazil remains an attractive longer-term growth opportunity, while the LiBBY study may lead to potential additional clinical development or regulatory pathways and/or strategic partnerships.

MediPharm Labs Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:MLZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:ROMJTSE:ROMJ58NeutralCAD 24.67M-14.43-4.00%―16.91%-244.25%
TSE:INNOTSE:INNO56NeutralCAD 7.42M-5.56-19.37%―-19.20%42.54%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:OILSTSE:OILS43NeutralCAD 4.26M-2.19-43.92%―-18.30%-397.37%
TSE:AVCNTSE:AVCN42NeutralCAD 12.09M-4.09-65.40%―-3.32%-34.15%
TSE:PCLOTSE:PCLO39UnderperformCAD 9.34M-2.6728.59%―0.90%57.73%

* Healthcare Sector Average

Performance Comparison

0%100%200%DE:MLZTSE:PCLOTSE:OILSTSE:ROMJTSE:AVCNTSE:INNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:MLZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:MLZMedipharm Labs (Otc)0.03-0.01-15.38%
TSE:PCLOPharmacielo0.050.0111.11%
TSE:OILSNextleaf Solutions 0.03-0.03-54.55%
TSE:ROMJRubicon Organics 0.36-0.09-18.89%
TSE:AVCNAvicanna Inc0.09-0.15-63.27%
TSE:INNOInnocan Pharma Corporation1.65-14.05-89.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.